Resilience is a biomanufacturing company that utilizes advanced technologies to produce complex medicines, including cell and gene therapies, while ensuring the integrity of biopharmaceutical supply chains. The company addresses the challenge of scaling production to meet the growing demand for innovative therapies by providing tailored, end-to-end manufacturing solutions.
Funding
$17.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AFFounders
Product
Problem
The biopharmaceutical industry faces challenges in scaling the production of complex medicines, such as cell and gene therapies, to meet increasing demand while maintaining the integrity of biopharmaceutical supply chains. Traditional manufacturing approaches often struggle to adapt to the unique requirements of these advanced therapies.
Solution
Resilience is a contract development and manufacturing organization (CDMO) focused on utilizing advanced technologies to manufacture complex medicines and ensure robust biopharmaceutical supply chains. The company offers tailored, end-to-end manufacturing solutions, encompassing drug substance and drug product manufacturing, to address the challenges of scaling production for innovative therapies. Resilience's approach integrates platform-based approaches, advanced analytics, and digital-first enterprise solutions to accelerate development, improve product quality, and reduce manufacturing costs. They provide expertise across various modalities, including biologics, vaccines, nucleic acids, gene therapy, and cell therapy, supporting programs from early-stage development through commercialization.
Target Audience
Resilience serves biopharmaceutical companies, ranging from small and mid-sized biotechs to large pharmaceutical organizations, as well as government and non-governmental organizations, seeking to develop and manufacture complex medicines.
Features
- End-to-end manufacturing solutions for drug substance and drug product.
- Platform-based approaches to streamline development and accelerate timelines.
- Capabilities for cell line development, process and analytical development (PAD), and GMP manufacturing.
- Expertise in viral vector manufacturing (AAV, LVV) with titers above industry standards.
- Modular autologous immune cell manufacturing platform (Auto-T™) for rapid development of GMP cell therapies.
- DAR-T™ platform for 3-day CAR-T cell manufacturing.
- Integrated formulation and fill/finish capabilities.
- Advanced analytical technologies for product characterization and release testing.
- Digital-first enterprise committed to cloud-based systems, AI, and data security.